Prostate cancer: Early enzalutamide substantially improves time to progression and overall survival when added to standard mHSPC therapy (testosterone suppression Ā± docetaxel)

An interim analysis of the international randomised, phase 3 ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer (mHSPC) who received the non-steroidal anti-androgen (NSAA) medicine enzalutamide along with the standard-of-care treatment were alive after 3 years...